Bayer HealthCare today announced that the company will present preclinical data that introduce investigational compounds for both therapy and imaging in its early oncology pipeline with unique and novel mechanisms at the American Association for Cancer Research (AACR) 102nd Annual Meeting, April 2-6, 2011, in Orlando, FL.
The annual AACR meeting highlights the latest discoveries and developments in oncology research.
Two of these compounds are BAY 87-2243, an inhibitor of hypoxia-inducible HIF-1α activation, and MT112/BAY 2010112, a BiTE® antibody, being developed in partnership with Micromet, Inc.
Data will also be presented on two compounds, BAY 94-9343, a mesothelin-targeting antibody-drug conjugate (ADC) developed in collaboration with ImmunoGen Inc., and BAY 79-4620, a CA9-targeted ADC developed in collaboration with Seattle Genetics, Inc.
These compounds are being developed to target antigens, mesothelin and carbonic anhydrase 9 (CA9), both of which are selectively expressed on certain tumors.
“The breadth and depth of research data being presented at this conference shows that Bayer is committed to researching and developing a wide variety of compounds and pathways in the hopes of discovering new, innovative ways to fight various types of cancer,” said Dr. Karl Ziegelbauer, Head of Therapeutic Research Group Oncology, Bayer HealthCare.
“We are excited to present this new research, which includes data on several of the latest compounds to enter clinical testing, as well as on those being evaluated in our companion diagnostics program, which may help us to identify patients who may benefit most from our medicines.”